<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00950365</url>
  </required_header>
  <id_info>
    <org_study_id>Pemetrexed/Erlotinib</org_study_id>
    <nct_id>NCT00950365</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Randomized Phase II Study of Schedule-Modulated Concomitant Pemetrexed and Erlotinib Versus Single Agent Pemetrexed in Patients With Progressive or Recurrent Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>OSI Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Erlotinib may stop the growth of tumor cells, and even shrink the tumors in some
      patients, by blocking some of the enzymes such as epidermal growth factor receptor (EGFR)
      needed for cell growth and spread. Pemetrexed is a drug that inhibits several key proteins
      that require folic acid to synthesize DNA. Blocking DNA synthesis in tumor cells has been
      shown to decrease tumor growth. can block tumor growth in different ways. Giving erlotinib
      together with pemetrexed at a specific schedule may kill more tumor cells than giving only
      pemetrexed.

      PURPOSE: This phase I/II trial is studying the side effects and best dose of erlotinib and
      cetuximab and to see how well they work in treating patients with advanced solid tumors or
      progressive or recurrent stage III or stage IV non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2006</start_date>
  <primary_completion_date type="Anticipated">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Every 6 weeks while on study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of pemetrexed and erlotinib combination</measure>
    <time_frame>Continously</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of molecular markers for biologic effects and predictive response</measure>
    <time_frame>while on study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pemetrexed Monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pharmacodynamic separation of pemetrexed and erlotinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>500 mg/m2 IV over 10 minutes on day 1 every 21 days</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed and erlotinib</intervention_name>
    <description>pemetrexed 500 mg/m2 IV over 10 minutes on day 1 every 21 days and erlotinib 150 mg PO once daily on days 2-17 every 21 days</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed advanced (Stage IIIB with
             a malignant pleural effusion or Stage IV disease) or recurrent nonsquamous NSCLC.

          -  Patients must have at least one measurable disease per RECIST criteria

          -  Patient must have disease progression after one prior chemotherapy and/or targeted
             therapy other than pemetrexed or anti-EGFR therapy for metastatic disease, or relapse
             while receiving adjuvant therapy, or within 12 months of completing adjuvant therapy

        Exclusion Criteria:

          -  Patients who have had immunotherapy, hormone, chemotherapy or radiotherapy within 4
             weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those
             who have not recovered from adverse events due to agents administered more than 4
             weeks earlier.

          -  Patients with uncontrolled brain metastases should be excluded from this clinical
             trial because of their poor prognosis.

          -  Patients with immune deficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tianhong Li, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tianhong Li, MD, PhD</last_name>
    <phone>718-904-2900</phone>
    <email>tli@montefiore.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cheryl Baker, APRN</last_name>
    <phone>718-405-8508</phone>
    <email>cbaker@montefiore.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Massachusetts</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bilal Piperdi, MD</last_name>
      <phone>508-856-3702</phone>
      <email>piperdib@ummhc.org</email>
    </contact>
    <investigator>
      <last_name>Bilal Piperdi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>William V Walsh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Cancer Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tianhong Li, MD, PhD</last_name>
      <phone>718-904-2900</phone>
      <email>tli@montefiore.org</email>
    </contact>
    <contact_backup>
      <last_name>Cheryl Baker, APRN</last_name>
      <phone>718-405-8508</phone>
      <email>cbaker@montefiore.org</email>
    </contact_backup>
    <investigator>
      <last_name>Tianhong Li, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rasim Gucalp, MD</last_name>
      <phone>718-920-4826</phone>
      <email>rgucalp@montefiore.org</email>
    </contact>
    <contact_backup>
      <last_name>Yoko Eng, RN</last_name>
      <phone>718-920-2090</phone>
      <email>yeng@montefiore.org</email>
    </contact_backup>
    <investigator>
      <last_name>Rasim Gucalp, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2009</study_first_submitted>
  <study_first_submitted_qc>July 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2009</study_first_posted>
  <last_update_submitted>July 30, 2009</last_update_submitted>
  <last_update_submitted_qc>July 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2009</last_update_posted>
  <responsible_party>
    <name_title>Tianhong Li, MD, PhD</name_title>
    <organization>Montefiore Medical Center</organization>
  </responsible_party>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>progressive or recurrent stage III or stage IV non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

